{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/entity/GYRE/timeline","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://api.morvs.ai/license","usage_info":"https://api.morvs.ai/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-10-10T11:44:40.998Z","methodology_url":"https://api.morvs.ai/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":212,"canonical_name":"GYRE THERAPEUTICS, INC.","cik":"0001124105","uei":null,"lei":null,"duns":null,"ticker":"GYRE"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","dol.form5500"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":57},"count":57,"timeline":[{"ts":"2026-07-16","kind":"sec.filing","form_type":"8-K","title":"8-K — GYRE THERAPEUTICS, INC. — 2026-07-16","url_slug":"/sec/cik-0001124105/8-k/0001140361-26-028716","accession_number":"0001140361-26-028716","importance":35},{"ts":"2026-07-15","kind":"sec.filing","form_type":"8-K/A","title":"8-K/A — GYRE THERAPEUTICS, INC. — 2026-07-15","url_slug":"/sec/cik-0001124105/8-k-a/0001140361-26-028564","accession_number":"0001140361-26-028564","importance":30},{"ts":"2026-07-13","kind":"sec.filing","form_type":"S-3/A","title":"S-3/A — GYRE THERAPEUTICS, INC. — 2026-07-13","url_slug":"/sec/cik-0001124105/s-3-a/0001140361-26-028333","accession_number":"0001140361-26-028333","importance":30},{"ts":"2026-06-30","kind":"sec.filing","form_type":"4","title":"4 — GYRE THERAPEUTICS, INC. — 2026-06-30","url_slug":"/sec/cik-0001124105/4/0001140361-26-027003","accession_number":"0001140361-26-027003","importance":30},{"ts":"2026-06-30","kind":"sec.filing","form_type":"4","title":"4 — GYRE THERAPEUTICS, INC. — 2026-06-30","url_slug":"/sec/cik-0001124105/4/0001140361-26-027004","accession_number":"0001140361-26-027004","importance":30},{"ts":"2026-06-30","kind":"sec.filing","form_type":"4","title":"4 — GYRE THERAPEUTICS, INC. — 2026-06-30","url_slug":"/sec/cik-0001124105/4/0001140361-26-027005","accession_number":"0001140361-26-027005","importance":30},{"ts":"2026-06-30","kind":"sec.filing","form_type":"4","title":"4 — GYRE THERAPEUTICS, INC. — 2026-06-30","url_slug":"/sec/cik-0001124105/4/0001140361-26-027006","accession_number":"0001140361-26-027006","importance":30},{"ts":"2026-06-30","kind":"sec.filing","form_type":"4","title":"4 — GYRE THERAPEUTICS, INC. — 2026-06-30","url_slug":"/sec/cik-0001124105/4/0001140361-26-027007","accession_number":"0001140361-26-027007","importance":30},{"ts":"2026-06-30","kind":"sec.filing","form_type":"4","title":"4 — GYRE THERAPEUTICS, INC. — 2026-06-30","url_slug":"/sec/cik-0001124105/4/0001140361-26-027008","accession_number":"0001140361-26-027008","importance":30},{"ts":"2026-06-23","kind":"sec.filing","form_type":"S-3","title":"S-3 — GYRE THERAPEUTICS, INC. — 2026-06-23","url_slug":"/sec/cik-0001124105/s-3/0001140361-26-025999","accession_number":"0001140361-26-025999","importance":30},{"ts":"2026-06-22","kind":"sec.filing","form_type":"4","title":"4 — GYRE THERAPEUTICS, INC. — 2026-06-22","url_slug":"/sec/cik-0001124105/4/0001140361-26-025950","accession_number":"0001140361-26-025950","importance":30},{"ts":"2026-06-18","kind":"sec.insider.s","reporter":"Ye Weiguo","title":"Chief Operating Officer","shares":3000,"price_per_share":6.35,"usd_value":19050,"security_title":"Common Stock","importance":35.01905},{"ts":"2026-06-18","kind":"sec.insider.m","reporter":"Ye Weiguo","title":"Chief Operating Officer","shares":3000,"price_per_share":0.75,"usd_value":2250,"security_title":"Common Stock","importance":15.00225},{"ts":"2026-06-16","kind":"sec.filing","form_type":"8-K","title":"8-K — GYRE THERAPEUTICS, INC. — 2026-06-16","url_slug":"/sec/cik-0001124105/8-k/0001140361-26-025324","accession_number":"0001140361-26-025324","importance":35},{"ts":"2026-06-15","kind":"sec.filing","form_type":"4","title":"4 — GYRE THERAPEUTICS, INC. — 2026-06-15","url_slug":"/sec/cik-0001124105/4/0001140361-26-025208","accession_number":"0001140361-26-025208","importance":30},{"ts":"2026-06-11","kind":"sec.insider.s","reporter":"Ye Weiguo","title":"Chief Operating Officer","shares":2800,"price_per_share":6.17,"usd_value":17276,"security_title":"Common Stock","importance":35.017276},{"ts":"2026-06-11","kind":"sec.filing","form_type":"4","title":"4 — GYRE THERAPEUTICS, INC. — 2026-06-11","url_slug":"/sec/cik-0001124105/4/0001140361-26-024929","accession_number":"0001140361-26-024929","importance":30},{"ts":"2026-06-11","kind":"sec.insider.m","reporter":"Ye Weiguo","title":"Chief Operating Officer","shares":2800,"price_per_share":0.75,"usd_value":2100,"security_title":"Common Stock","importance":15.0021},{"ts":"2026-06-10","kind":"sec.insider.s","reporter":"Ye Weiguo","title":"Chief Operating Officer","shares":6418,"price_per_share":6.21,"usd_value":39856,"security_title":"Common Stock","importance":35.03985578},{"ts":"2026-06-10","kind":"sec.insider.s","reporter":"Ye Weiguo","title":"Chief Operating Officer","shares":5000,"price_per_share":6.24,"usd_value":31200,"security_title":"Common Stock","importance":35.0312},{"ts":"2026-06-10","kind":"sec.filing","form_type":"4","title":"4 — GYRE THERAPEUTICS, INC. — 2026-06-10","url_slug":"/sec/cik-0001124105/4/0001140361-26-024784","accession_number":"0001140361-26-024784","importance":30},{"ts":"2026-06-10","kind":"sec.filing","form_type":"4","title":"4 — GYRE THERAPEUTICS, INC. — 2026-06-10","url_slug":"/sec/cik-0001124105/4/0001140361-26-024785","accession_number":"0001140361-26-024785","importance":30},{"ts":"2026-06-10","kind":"sec.filing","form_type":"S-8","title":"S-8 — GYRE THERAPEUTICS, INC. — 2026-06-10","url_slug":"/sec/cik-0001124105/s-8/0001140361-26-024702","accession_number":"0001140361-26-024702","importance":30},{"ts":"2026-06-10","kind":"sec.insider.m","reporter":"Ye Weiguo","title":"Chief Operating Officer","shares":6418,"price_per_share":0.75,"usd_value":4814,"security_title":"Common Stock","importance":15.0048135},{"ts":"2026-06-10","kind":"sec.insider.m","reporter":"Ye Weiguo","title":"Chief Operating Officer","shares":5000,"price_per_share":0.75,"usd_value":3750,"security_title":"Common Stock","importance":15.00375},{"ts":"2026-06-09","kind":"sec.insider.s","reporter":"Ye Weiguo","title":"Chief Operating Officer","shares":14500,"price_per_share":6.14,"usd_value":89030,"security_title":"Common Stock","importance":35.08903},{"ts":"2026-06-09","kind":"sec.insider.s","reporter":"Ye Weiguo","title":"Chief Operating Officer","shares":3000,"price_per_share":6.15,"usd_value":18450,"security_title":"Common Stock","importance":35.01845},{"ts":"2026-06-09","kind":"sec.insider.m","reporter":"Ye Weiguo","title":"Chief Operating Officer","shares":14500,"price_per_share":0.75,"usd_value":10875,"security_title":"Common Stock","importance":15.010875},{"ts":"2026-06-09","kind":"sec.insider.m","reporter":"Ye Weiguo","title":"Chief Operating Officer","shares":3000,"price_per_share":0.75,"usd_value":2250,"security_title":"Common Stock","importance":15.00225},{"ts":"2026-06-08","kind":"sec.filing","form_type":"4","title":"4 — GYRE THERAPEUTICS, INC. — 2026-06-08","url_slug":"/sec/cik-0001124105/4/0001140361-26-024449","accession_number":"0001140361-26-024449","importance":30},{"ts":"2026-06-05","kind":"sec.insider.s","reporter":"Ye Weiguo","title":"Chief Operating Officer","shares":15401,"price_per_share":6.4,"usd_value":98566,"security_title":"Common Stock","importance":35.0985664},{"ts":"2026-06-05","kind":"sec.insider.15401","reporter":"Ye Weiguo","title":"Chief Operating Officer","shares":15401,"price_per_share":6.4,"usd_value":98566,"security_title":"Common Stock","importance":15.0985664},{"ts":"2026-06-05","kind":"sec.insider.15401","reporter":"Ye Weiguo","title":"Chief Operating Officer","shares":15401,"price_per_share":0.75,"usd_value":11551,"security_title":"Common Stock","importance":15.01155075},{"ts":"2026-06-05","kind":"sec.insider.m","reporter":"Ye Weiguo","title":"Chief Operating Officer","shares":15401,"price_per_share":0.75,"usd_value":11551,"security_title":"Common Stock","importance":15.01155075},{"ts":"2026-06-04","kind":"sec.insider.s","reporter":"Ye Weiguo","title":"Chief Operating Officer","shares":19575,"price_per_share":6.13,"usd_value":119995,"security_title":"Common Stock","importance":35.11999475},{"ts":"2026-06-04","kind":"sec.insider.19575","reporter":"Ye Weiguo","title":"Chief Operating Officer","shares":19575,"price_per_share":6.13,"usd_value":119995,"security_title":"Common Stock","importance":15.11999475},{"ts":"2026-06-04","kind":"sec.insider.19575","reporter":"Ye Weiguo","title":"Chief Operating Officer","shares":19575,"price_per_share":0.75,"usd_value":14681,"security_title":"Common Stock","importance":15.01468125},{"ts":"2026-06-04","kind":"sec.insider.m","reporter":"Ye Weiguo","title":"Chief Operating Officer","shares":19575,"price_per_share":0.75,"usd_value":14681,"security_title":"Common Stock","importance":15.01468125},{"ts":"2026-06-02","kind":"sec.filing","form_type":"8-K","title":"8-K — GYRE THERAPEUTICS, INC. — 2026-06-02","url_slug":"/sec/cik-0001124105/8-k/0001140361-26-023625","accession_number":"0001140361-26-023625","importance":35},{"ts":"2026-05-20","kind":"sec.filing","form_type":"4","title":"4 — GYRE THERAPEUTICS, INC. — 2026-05-20","url_slug":"/sec/cik-0001124105/4/0001140361-26-022235","accession_number":"0001140361-26-022235","importance":30},{"ts":"2026-05-20","kind":"sec.filing","form_type":"4","title":"4 — GYRE THERAPEUTICS, INC. — 2026-05-20","url_slug":"/sec/cik-0001124105/4/0001140361-26-022303","accession_number":"0001140361-26-022303","importance":30},{"ts":"2026-05-19","kind":"sec.insider.s","reporter":"Ye Weiguo","title":"Chief Operating Officer","shares":9120,"price_per_share":6.37,"usd_value":58094,"security_title":"Common Stock","importance":35.0580944},{"ts":"2026-05-19","kind":"sec.insider.m","reporter":"Ye Weiguo","title":"Chief Operating Officer","shares":9120,"price_per_share":0.75,"usd_value":6840,"security_title":"Common Stock","importance":15.00684},{"ts":"2026-05-18","kind":"sec.insider.s","reporter":"Ye Weiguo","title":"Chief Operating Officer","shares":200,"price_per_share":6.62,"usd_value":1324,"security_title":"Common Stock","importance":35.001324},{"ts":"2026-05-18","kind":"sec.filing","form_type":"4","title":"4 — GYRE THERAPEUTICS, INC. — 2026-05-18","url_slug":"/sec/cik-0001124105/4/0001140361-26-021889","accession_number":"0001140361-26-021889","importance":30},{"ts":"2026-05-18","kind":"sec.insider.m","reporter":"Ye Weiguo","title":"Chief Operating Officer","shares":200,"price_per_share":0.75,"usd_value":150,"security_title":"Common Stock","importance":15.00015},{"ts":"2026-05-15","kind":"sec.insider.s","reporter":"Ye Weiguo","title":"Chief Operating Officer","shares":13100,"price_per_share":6.65,"usd_value":87115,"security_title":"Common Stock","importance":35.087115},{"ts":"2026-05-15","kind":"sec.insider.m","reporter":"Ye Weiguo","title":"Chief Operating Officer","shares":13100,"price_per_share":0.75,"usd_value":9825,"security_title":"Common Stock","importance":15.009825},{"ts":"2026-05-14","kind":"sec.insider.s","reporter":"Ye Weiguo","title":"Chief Operating Officer","shares":15580,"price_per_share":6.91,"usd_value":107658,"security_title":"Common Stock","importance":35.1076578},{"ts":"2026-05-14","kind":"sec.filing","form_type":"8-K","title":"8-K — GYRE THERAPEUTICS, INC. — 2026-05-14","url_slug":"/sec/cik-0001124105/8-k/0001140361-26-021360","accession_number":"0001140361-26-021360","importance":35},{"ts":"2026-05-14","kind":"sec.insider.m","reporter":"Ye Weiguo","title":"Chief Operating Officer","shares":15580,"price_per_share":0.75,"usd_value":11685,"security_title":"Common Stock","importance":15.011685},{"ts":"2026-05-12","kind":"sec.filing","form_type":"8-K","title":"8-K — GYRE THERAPEUTICS, INC. — 2026-05-12","url_slug":"/sec/cik-0001124105/8-k/0001140361-26-020845","accession_number":"0001140361-26-020845","importance":35},{"ts":"2026-05-11","kind":"sec.filing","form_type":"144","title":"144 — GYRE THERAPEUTICS, INC. — 2026-05-11","url_slug":"/sec/cik-0001124105/144/0001985496-26-000001","accession_number":"0001985496-26-000001","importance":30},{"ts":"2026-05-08","kind":"sec.filing","form_type":"10-Q","title":"10-Q — GYRE THERAPEUTICS, INC. — 2026-05-08","url_slug":"/sec/cik-0001124105/10-q/0001193125-26-214676","accession_number":"0001193125-26-214676","importance":45},{"ts":"2026-04-27","kind":"sec.filing","form_type":"DEF 14A","title":"DEF 14A — GYRE THERAPEUTICS, INC. — 2026-04-27","url_slug":"/sec/cik-0001124105/def-14a/0001140361-26-017124","accession_number":"0001140361-26-017124","importance":40},{"ts":"2026-04-27","kind":"sec.filing","form_type":"ARS","title":"ARS — GYRE THERAPEUTICS, INC. — 2026-04-27","url_slug":"/sec/cik-0001124105/ars/0001140361-26-017132","accession_number":"0001140361-26-017132","importance":30},{"ts":"2026-04-27","kind":"sec.filing","form_type":"DEFA14A","title":"DEFA14A — GYRE THERAPEUTICS, INC. — 2026-04-27","url_slug":"/sec/cik-0001124105/defa14a/0001140361-26-017130","accession_number":"0001140361-26-017130","importance":30}]}